AIMS/HYPOTHESIS: Methylglyoxal (MGO) is a major precursor for advanced glycation end-products (AGEs), which are thought to play a role in vascular complications in diabetes. Known MGO-arginine-derived AGEs are 5-hydro-5-methylimidazolone (MG-H1), argpyrimidine and tetrahydropyrimidine (THP). We studied THP in relation to type 1 diabetes, endothelial dysfunction, low-grade inflammation, vascular complications and atherosclerosis. METHODS: We raised and characterised a monoclonal antibody against MGO-derived THP. We measured plasma THP with a competitive ELISA in two cohort studies: study A (198 individuals with type 1 diabetes and 197 controls); study B (individuals with type 1 diabetes, 175 with normoalbuminuria and 198 with macroalbuminuria [>300 mg/24 h]). We measured plasma markers of endothelial dysfunction and low-grade inflammation, and evaluated the presence of THP and N (ε)-(carboxymethyl)lysine (CML) in atherosclerotic arteries. RESULTS: THP was higher in individuals with type 1 diabetes than in those without (median [interquartile range] 115.5 U/μl [102.4-133.2] and 109.8 U/μl [91.8-122.3], respectively; p = 0.03). THP was associated with plasma soluble vascular cell adhesion molecule 1 in both study A (standardised β = 0.48 [95% CI 0.38, 0.58]; p < 0.001) and study B (standardised β = 0.31 [95% CI 0.23, 0.40]; p < 0.001), and with secreted phospholipase A2 (standardised β = 0.26 [95% CI 0.17, 0.36]; p < 0.001) in study B. We found no association of THP with micro- or macro-vascular complications. Both THP and CML were detected in atherosclerotic arteries. CONCLUSIONS/ INTERPRETATION: Our results suggest that MGO-derived THP may reflect endothelial dysfunction among individuals with and without type 1 diabetes, and therefore may potentially play a role in the development of atherosclerosis and vascular disease.
AIMS/HYPOTHESIS: Methylglyoxal (MGO) is a major precursor for advanced glycation end-products (AGEs), which are thought to play a role in vascular complications in diabetes. Known MGO-arginine-derived AGEs are 5-hydro-5-methylimidazolone (MG-H1), argpyrimidine and tetrahydropyrimidine (THP). We studied THP in relation to type 1 diabetes, endothelial dysfunction, low-grade inflammation, vascular complications and atherosclerosis. METHODS: We raised and characterised a monoclonal antibody against MGO-derived THP. We measured plasma THP with a competitive ELISA in two cohort studies: study A (198 individuals with type 1 diabetes and 197 controls); study B (individuals with type 1 diabetes, 175 with normoalbuminuria and 198 with macroalbuminuria [>300 mg/24 h]). We measured plasma markers of endothelial dysfunction and low-grade inflammation, and evaluated the presence of THP and N (ε)-(carboxymethyl)lysine (CML) in atherosclerotic arteries. RESULTS:THP was higher in individuals with type 1 diabetes than in those without (median [interquartile range] 115.5 U/μl [102.4-133.2] and 109.8 U/μl [91.8-122.3], respectively; p = 0.03). THP was associated with plasma soluble vascular cell adhesion molecule 1 in both study A (standardised β = 0.48 [95% CI 0.38, 0.58]; p < 0.001) and study B (standardised β = 0.31 [95% CI 0.23, 0.40]; p < 0.001), and with secreted phospholipase A2 (standardised β = 0.26 [95% CI 0.17, 0.36]; p < 0.001) in study B. We found no association of THP with micro- or macro-vascular complications. Both THP and CML were detected in atherosclerotic arteries. CONCLUSIONS/ INTERPRETATION: Our results suggest that MGO-derived THP may reflect endothelial dysfunction among individuals with and without type 1 diabetes, and therefore may potentially play a role in the development of atherosclerosis and vascular disease.
Authors: C G Schalkwijk; D C Poland; W van Dijk; A Kok; J J Emeis; A M Dräger; A Doni; V W van Hinsbergh; C D Stehouwer Journal: Diabetologia Date: 1999-03 Impact factor: 10.122
Authors: K D O'Brien; M D Allen; T O McDonald; A Chait; J M Harlan; D Fishbein; J McCarty; M Ferguson; K Hudkins; C D Benjamin Journal: J Clin Invest Date: 1993-08 Impact factor: 14.808
Authors: L Tarnow; F Cambien; P Rossing; F S Nielsen; B V Hansen; L Lecerf; O Poirier; S Danilov; S Boelskifte; K Borch-Johnsen Journal: Diabetologia Date: 1995-07 Impact factor: 10.122
Authors: R A Smulders; C D Stehouwer; C G Schalkwijk; A J Donker; V W van Hinsbergh; J M TeKoppele Journal: Thromb Haemost Date: 1998-07 Impact factor: 5.249
Authors: Jeremy N Adams; Susan E Martelle; Laura M Raffield; Barry I Freedman; Carl D Langefeld; Fang-Chi Hsu; Joseph A Maldjian; Jeff D Williamson; Christina E Hugenschmidt; J Jeffery Carr; Amanda J Cox; Donald W Bowden Journal: J Diabetes Complications Date: 2015-11-30 Impact factor: 2.852
Authors: Yan Ping Sun; Jun Fei Gu; Xiao Bin Tan; Chun Fei Wang; Xiao Bin Jia; Liang Feng; Ji Ping Liu Journal: Mol Med Rep Date: 2015-12-28 Impact factor: 2.952
Authors: Sebastian Brings; Thomas Fleming; Marc Freichel; Martina U Muckenthaler; Stephan Herzig; Peter P Nawroth Journal: Int J Mol Sci Date: 2017-05-05 Impact factor: 5.923
Authors: Marcelle G A van Eupen; Miranda T Schram; Helen M Colhoun; Jean L J M Scheijen; Coen D A Stehouwer; Casper G Schalkwijk Journal: Cardiovasc Diabetol Date: 2013-10-17 Impact factor: 9.951